BioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 7.1% in October

BioAtla, Inc. (NASDAQ:BCAB) saw a large decline in short interest in October. As of October 31st, there was short interest totalling 4,870,000 shares, a decline of 7.1% from the October 15th total of 5,240,000 shares. Based on an average daily trading volume, of 1,210,000 shares, the days-to-cover ratio is currently 4.0 days.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on BCAB shares. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price objective on shares of BioAtla in a report on Monday, September 16th. HC Wainwright lowered BioAtla from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 13th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of BCAB. Vanguard Group Inc. boosted its stake in shares of BioAtla by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 2,099,037 shares of the company’s stock worth $7,221,000 after acquiring an additional 17,667 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of BioAtla by 57.6% in the 1st quarter. Acadian Asset Management LLC now owns 155,188 shares of the company’s stock valued at $532,000 after purchasing an additional 56,748 shares during the period. Price T Rowe Associates Inc. MD purchased a new position in BioAtla in the 1st quarter worth about $45,000. Virtu Financial LLC acquired a new stake in BioAtla during the 1st quarter worth about $103,000. Finally, Rinkey Investments purchased a new stake in BioAtla during the second quarter valued at about $35,000. Institutional investors own 77.23% of the company’s stock.

BioAtla Trading Down 8.8 %

Shares of BioAtla stock opened at $1.56 on Monday. BioAtla has a 52 week low of $1.14 and a 52 week high of $4.02. The stock has a market cap of $75.43 million, a PE ratio of -0.92 and a beta of 1.03. The company’s 50-day moving average price is $1.91 and its two-hundred day moving average price is $1.86.

BioAtla (NASDAQ:BCAB) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.12. The business had revenue of $11.00 million during the quarter. During the same quarter in the prior year, the company earned ($0.70) earnings per share. On average, equities analysts predict that BioAtla will post -1.49 EPS for the current fiscal year.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.